...A. Overview: This year has been catalyst-rich and strategically important: 1. Enabling Co. to conclude 2022 in position of significant strength. a. b. Setting IONS up for substantial growth. 2. Looking forward to potentially adding two new commercial products from rich Phase 3 pipeline to portfolio next year. Eplontersen for ATTR polyneuropathy. a. b. Tofersen for SOD1-ALS. 3. Made excellent progress, advancing late- and mid-stage pipeline. 4. With eight positive key data readouts so far this year, rich Phase 3 pipeline is poised to expand two new Phase 3 starts expected in 1H23. 5. Based on all pipeline progress, well-positioned to continue delivering steady cadence of Phase 3 data readouts in 2023, 2024, 2025 and beyond. 6. This year, advanced commitment to deliver transformative medicines to market with go-to-market commercial preparations for near-term product opportunities: Eplontersen. a. b. Olezarsen. c. Donidalorsen. 7. Made great progress, expanding and diversifying technology...
